so-Called “living drugs,” offer great potential to cure diseases and to combat the symptoms, as is often the case. The only research initiative “Restore” of the center for Regenerative therapies the Berlin Institute of Health (BIH), the Charité hospital, working on the implementation of such novel therapy methods, but also the European Commission thinks not.
you will support the interdisciplinary project, in which other European research institutions and companies are involved, now, with start-up funding of one Million euros, as the BIH announced on Thursday. Thus, the invitation to develop this concept further and to expand the circle of researchers and institutions, in order to bring Europe in the field of “advanced therapies” (novel therapies) to the top.
hurdles in the implementation of new therapies into the clinical routine
Under the “advanced therapies” includes, for example, tissue preparations, and cell and gene therapy products, such as in the laboratory-grown cartilage cells or genetically modified cells for use against blood cancer. You could revolutionize according to Hans Dieter Volk, who coordinates the project, “health care”. Now, more and more success stories were recorded in which patients could be cured in the terminal stage of their illness. To be able to use the new methods and biomaterials in clinical practice, there are still a couple of hurdles, both in technical terms and in terms of manufacturing, clinical Management, and reimbursement.
“Restore” to overcome these obstacles now, so that “every Patient in Europe can benefit from these novel treatment approaches, will get the opportunity,” says the immunologist, who directs the center for Regenerative therapies Berlin Institute of Health. It was a matter of promising research results into safe and accessible methods of treatment.
More research funds in views
The core team of the health initiative consists of an international, interdisciplinary research institutes and Biotech companies. More than 250 experts from science, as well as representatives of non-profit organizations and patient associations have pledged their support for the project and on the significant scientific, economic and social potential of the “living drugs” referred to.
If the consortium continues to work successfully, it could be used as a large-scale research initiative of the European Union in the framework of the “Large-Scale Research Initiative” can be established. This should in the long term, up to one billion euros available, which can be invested in research into new therapies.
More about
the First gene therapy against cancer Living medication
Hartmut Wewetzer
Twelve of the Newsletter, twelve districts: Our people-the Newsletter from all districts of Berlin you can order it free of charge: leute.tagesspiegel.de
